UniCredit Call 10 ATO 18.12.2024/ DE000HC8H990 /
07/10/2024 09:20:05 | Chg.0.000 | Bid09:20:21 | Ask09:20:21 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.001EUR | 0.00% | 0.001 Bid Size: 125,000 |
- Ask Size: - |
Atos SE | 10.00 - | 18/12/2024 | Call |
GlobeNewswire
21/08
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
21/08
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire
20/08
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Publi...
GlobeNewswire
14/08
Stevie® Awards Announce Winners in The 21st Annual International Business Awards® from Across the Gl...
GlobeNewswire
12/08
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
30/07
HUMAN Releases The Quadrillion Report: 2024 Cyberthreat Benchmarks, Uncovers Nearly 150 Million Comp...
GlobeNewswire
22/07
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE...
GlobeNewswire
28/06
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire
30/05
Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets
GlobeNewswire
28/05
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...
GlobeNewswire
16/05
Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire
15/05
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire
13/05
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
29/04
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...